Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Safety and Efficacy of Donepezil 10 mg/day in Patients with Mild to Moderate Alzheimer's Disease.

Journal of Alzheimer's disease : JAD - 1 Jan 2020

Jia Jianping, Wei Cuibai, Chen Wei, Jia Longfei, Zhou Aihong, Wang Fen, Tang Yi, Xu Luoyi

Abstract excerpt

BACKGROUND: Efficacy and dose-effect relationship of donepezil for treating patients with Alzheimer's disease (AD) have been proven. However, few studies focused on the safety of donepezil, particularly in Chinese patients. OBJECTIVE: To assess the safety of donepezil 10 mg/day in Chinese patients with mild-to-moderate AD. METHODS: In this single-arm, prospective, multicenter trial, 241 patients with mild to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alzheimer Disease
Share to Apolipoprotein E4

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Apolipoproteins E

Share to Cholinesterase Inhibitors

Share to Dose-Response Relationship, Drug

Share to Drug Interactions

Share to Electrocardiography

Share to Mental Status and Dementia Tests

Source

Identifiers

PMID: 31985467
DOI: 10.3233/JAD-190940

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Safety and Efficacy of Donepezil 10 mg/day in Patients with Mild to Moderate Alzheimer's Disease.PMID 31985467Read ↗

Clinical effects of high oral dose of donepezil for patients with Alzheimer's disease in Japan.Semantic proximity Read ↗

Effect of CYP2D6*10 and APOE polymorphisms on the efficacy of donepezil in patients with Alzheimer's disease.Semantic proximity Read ↗

Effect of the CYP2D6 and APOE Polymorphisms on the Efficacy of Donepezil in Patients with Alzheimer's Disease: A Systematic Review and Meta-Analysis.Semantic proximity Read ↗

Cilostazol as an add-on therapy for patients with Alzheimer's disease in Taiwan: a case control study.Semantic proximity Read ↗

Safety, tolerability and efficacy outcomes of the Investigation of Levetiracetam in Alzheimer’s Disease (ILiAD) trialSemantic proximity Read ↗

Effect of a CYP2D6 polymorphism on the efficacy of donepezil in patients with Alzheimer disease.Semantic proximity Read ↗

Impact of the CYP2D6 single nucleotide polymorphism on the concentration of and therapeutic response to donepezil in mild-to-moderate Alzheimer's disease.Semantic proximity Read ↗

Geographic variation in dementia-related adverse events associated with sacubitril/valsartan: Analysis of the FDA Adverse Event Reporting SystemSemantic proximity Read ↗

Clinical Response to Donepezil in Mild and Moderate Dementia: Relationship to Drug Plasma Concentration and CYP2D6 and APOE Genetic Polymorphisms.Semantic proximity Read ↗

Effectiveness of Nootropics in Combination with Cholinesterase Inhibitors on Cognitive Function in Mild-to-Moderate Dementia: A Study Using Real-world DataSemantic proximity Read ↗

A Targeted Approach: Understanding the Role of Ginkgo Biloba in Varied Dementia Patient ProfilesSemantic proximity Read ↗

Effect of Apolipoprotein E ɛ4 Carrier Status on Cognitive Response to Acetylcholinesterase Inhibitors in Patients with Alzheimer's Disease: A Systematic Review and Meta-Analysis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.